Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 3/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 13/20 | 0.49 |
| ▸ | IGF1R | P08069 | 11/20 | 0.49 |
| ▸ | RET | P07949 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | PAK4 | O96013 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248784 | 0.89 | KDR (0.48) | PTK2ALKIGF1RRETPDGFRB | |
| SCHEMBL4250254 | 0.83 | PTK2 (0.54) | PTK2ALKIGF1RRETAURKA | |
| SCHEMBL4251626 | 0.83 | ALK (0.59) | PTK2ALKIGF1RRETAURKA | |
| SCHEMBL13911389 | 0.83 | ROCK1 (0.44) | ALKRETAURKAPIM1FGFR1 | |
| SCHEMBL5760237 | 0.82 | PTK2 (0.58) | PTK2ALKIGF1RRETAURKA | |
| SCHEMBL4660744 | 0.81 | CDK2 (0.48) | ALKIGF1RABL1KDRCDK7 | |
| SCHEMBL5758488 | 0.80 | ALK (0.73) | PTK2ALKIGF1RRETAURKA | |
| SCHEMBL4245377 | 0.80 | RET (0.39) | RETAURKAJAK2PDGFRAKDR | |
| SCHEMBL27760699 | 0.79 | ROCK1 (0.38) | RETAURKAJAK2MAPK8CDK7 | |
| SCHEMBL4247112 | 0.78 | IKBKB (0.43) | PTK2RETAURKAJAK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069360-A1 | Organic Compounds | CARAVATTI, GIORGIO (CH) | 2009-03-12 | — | — | US | disclosed |
| EP-2001864-A1 | HETEROCYCLIC ORGANIC COMPOUNDS FOR THE TREATMENT OF IN PARTICULAR MELANOMA | Novartis Pharma AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007109045-A1 | HETEROCYCLIC ORGANIC COMPOUNDS FOR THE TREATMENT OF IN PARTICULAR MELANOMA | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069360-A1 | Organic Compounds | BRAF, MAP3K1, RAF1 | PTK2 51/4885ALK 67/4885IGF1R 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.